Caplyta (lumateperone) costs roughly $1,762 for a 30-day supply at list price, making it one of the more expensive antipsychotic medications on the market. Several factors drive that price: it’s a brand-name drug with no generic competition, it works through a mechanism unlike any other antipsychotic, and the company that developed it spent years and hundreds of millions of dollars bringing it to market. Here’s what’s behind the price tag and what you can do about it.
What Caplyta Actually Costs
Regardless of the dose you take (10.5 mg, 21 mg, or 42 mg), the list price starts at about $1,762 for 30 capsules. That’s the wholesale price before insurance, and it’s the number your pharmacy sees if you’re paying out of pocket. For context, generic versions of older antipsychotics like quetiapine or risperidone can cost under $30 a month. That gap is enormous, and it’s the core reason people search for answers about Caplyta’s cost.
No Generic Competition Until at Least 2029
The single biggest reason Caplyta is expensive is patent protection. The key U.S. patent (No. 8,648,077) has an original expiration date of December 1, 2029, and the manufacturer has applied for a patent term extension that could push exclusivity out to June 2033. Until those patents expire and generic manufacturers can enter the market, Intra-Cellular Therapies is the only company that can sell lumateperone. That monopoly gives the company full control over pricing.
This is the same dynamic behind nearly every expensive brand-name drug. Generic competition typically drops a medication’s price by 80% or more, but that relief is still years away for Caplyta.
A Drug That Works Differently From Older Options
Caplyta isn’t just another version of an existing antipsychotic. It has a genuinely novel mechanism that affects three brain signaling systems at once: dopamine, serotonin, and glutamate. It’s the first antipsychotic that also acts on glutamate receptors, which are thought to play a role in mood and cognition. Most older antipsychotics work primarily by blocking dopamine receptors.
What makes this clinically relevant, and what the manufacturer uses to justify the price, is the side effect profile. Older antipsychotics are notorious for causing significant weight gain, blood sugar problems, and elevated cholesterol. Caplyta has a notably milder metabolic footprint. In studies of patients with bipolar depression, the rate of new-onset metabolic syndrome was essentially the same as placebo (10.8% versus 10.7%). When patients with schizophrenia switched to Caplyta from other antipsychotics, 19% experienced clinically significant weight loss, and 28% of overweight patients moved back to a normal BMI category. Compared head-to-head with risperidone, Caplyta produced lower levels of blood sugar, cholesterol, and triglycerides.
Caplyta also needs to occupy only about 40% of dopamine receptors to be effective, which is unusually low for an antipsychotic. That lighter touch on the dopamine system is thought to explain why it causes fewer movement-related side effects. The drug is selective for brain pathways involved in mood and psychosis while largely sparing the pathways that control motor function.
R&D Costs and an Expanding Label
Intra-Cellular Therapies spent years developing Caplyta through multiple large clinical trial programs. The company reported research and development expenses of $89.1 million in 2019 alone, the year the FDA first approved the drug for schizophrenia. It also owed milestone payments to Bristol-Myers Squibb at every major development stage, totaling at least $10.75 million through FDA approval, with additional payments tied to international approvals.
Since launch, the company has continued investing to expand Caplyta’s approved uses. The FDA now clears it for three conditions: schizophrenia in adults, depressive episodes in bipolar I or II disorder (as a standalone treatment or combined with a mood stabilizer), and as an add-on to antidepressants for major depressive disorder. Each new indication required its own set of clinical trials, and the company prices the drug to recoup those costs across its patent-protected window.
Insurance Often Requires You to Try Cheaper Drugs First
Most insurers don’t cover Caplyta without restrictions. Aetna’s 2025 policy is a typical example: before approving Caplyta, they require that you’ve already tried and failed (or can’t tolerate) at least one of several cheaper generic antipsychotics, including aripiprazole, olanzapine, quetiapine, risperidone, paliperidone, or ziprasidone. This is called step therapy, and it’s standard for expensive brand-name psychiatric medications.
If you meet those criteria and get approved, your copay depends on your specific plan. But if you’re denied or stuck in a coverage gap, the full price lands on you.
How to Lower Your Out-of-Pocket Cost
The manufacturer offers a copay savings program for people with private commercial insurance. Eligible patients can pay as little as $0 on their first two fills. After that, the card covers up to $700 per 30-day prescription. If you’re taking Caplyta as an add-on treatment for major depressive disorder, the program also covers up to $100 per fill toward a generic antidepressant. The program runs through December 31, 2026.
There are important restrictions. You must be 18 or older, have a valid prescription for an FDA-approved use, and carry private commercial insurance. The savings card does not work if you’re covered by Medicare, Medicaid, TRICARE, or other government programs. Cash discount cards also can’t be combined with it.
For people without insurance or on government plans, the options are more limited. Some patients qualify for the manufacturer’s patient assistance program, which is a separate application process. Others work with their prescriber to appeal insurance denials or explore therapeutic alternatives that achieve similar goals at a lower cost.
The Bottom Line on Pricing
Caplyta is expensive because it’s a patented, first-in-class medication with no generic equivalent, sold by a single company that spent heavily to develop it and bring it through FDA approval for three psychiatric conditions. Its favorable side effect profile, particularly around weight and metabolic health, gives the manufacturer leverage to charge a premium over older generics. That pricing power will persist until patent expiration opens the door to generic competition, which is unlikely before 2029 at the earliest.